2017 American Transplant Congress
CD4+IFN-γ+IL-10+ Regulatory Type 1 Cells Facilitate Prolongation of Graft Survival in Old Recipient Mice Treated with Rapamycin.
Although the elderly represent a rapidly growing population among transplant recipients, age-specific aspects have not been considered sufficiently in clinical trials. Moreover, age-specific effects of…2017 American Transplant Congress
Conversion from Calcineurin Inhibitor to Sirolimus in Kidney Transplantation Recipients with Malignancy.
Nephrology, Asan Medical Center, Seoul, Republic of Korea
Background: Kidney transplant recipients are at an increased risk of malignancy for various reasons, such as the chronic use of calcineurin inhibitor (CNI). Sirolimus (SRL),…2017 American Transplant Congress
Efficacy of Calcineurin Inhibitors Transferring to Rapamycin in Live Kidney Transplantation from Old Donors to Young Recipients.
Organ Transplant Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
Background Calcineurin inhibitor(CNI) nephrotoxicity is one of the major reasons for chronic allograft injury in live kidney transplantation from old donors to young recipients. Therefore…2016 American Transplant Congress
Effect of mTOR Inhibitors on the Risk of Cancer Development After Kidney Transplantation in Chinese Population.
Introduction The mTOR inhibitor is an immunosuppressive drug used in kidney transplantation. Whether the mTOR inhibitors is associated with reduced risk of cancer development in…2016 American Transplant Congress
The mTORC2 Activation Is Critical for Hepato-Cytoprotection Against Ischemia and Reperfusion Injury.
Background & AimsRapamycin and Everolimus have been used in liver transplant patients, particularly those with calcineurin inhibitor-related nephrotoxicity and hepatocellular carcinoma. Although designed as mTORC1…2016 American Transplant Congress
Peritransplant Costimulation Blockade Combined with a Short-Course of Rapamycin Prevents Rejection of Vascularized Composite Allografts.
[Background] Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss. Routine clinical application, however, is hampered by the toxicity of long-term maintenance immunosuppression.…2016 American Transplant Congress
Heterologous Persistent and Latent Viral Infections Do Not Impact Graft Survival.
1Duke University, Durham; 2Emory University, Atlanta.
Purpose: Infection induces costimulation-resistant memory T cells with heterologous alloreactivity. Rapamycin has been shown to mitigate the effect of these cells in transplant rejection. Previous…2016 American Transplant Congress
The Impact of a Novel Dual Adenosine Triphosphate-Competitive mTOR Inhibitor (TORKinib) on Alloimmunity and Transplant Survival.
Background: Rapamycin (RAPA), an immunosuppressive agent, inhibits the mechanistic target of Rapamycin (mTOR), the kinase subunit of two mTOR- containing complexes (mTORC1 and mTORC2). While…2016 American Transplant Congress
Rapamycin Prolongs Cardiac Allograft Survival in a Mouse Model by Inducing Myeloid-Derived Suppressor Cells.
Mammalian target of rapamycin (mTOR) inhibitors are the main immunosuppressive drugs for organ transplant recipients. Nevertheless, the mechanisms by which mTOR inhibitors induce immunosuppression is…2016 American Transplant Congress
Only 13% of Liver Transplant (LT) Recipients with Moderate to Severe Kidney Disease (KD) Tolerate Conversion to Everolimus and Reduced Tacrolimus (EVR/rTac).
Liver Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
EVR/rTac has been reported to improve renal function in LT recipients with adequate kidney function (eGFR > 80ml/min); however, this strategy in LT patients with…
American Transplant Congress abstracts